Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker TRVI · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-… NCT07868419 · Idiopathic Pulmonary Fibrosis NAL ER, Placebo | TRVI Trevi Therapeutics | Phase 3 | Recruiting | 201 | Aug 2027 | Registry ↗ |
| Nov 13, 2026 | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Releas… NCT07671911 · Idiopathic Pulmonary Fibrosis NAL ER, Placebo | TRVI Trevi Therapeutics | Phase 3 | Recruiting | 306 | Jun 2028 | Registry ↗ |
| Nov 5, 2026 | The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic… NCT07671924 · Refractory Chronic Cough NAL ER, Placebo | TRVI Trevi Therapeutics | Phase 2 | Recruiting | 100 | Sep 2027 | Registry ↗ |
| Aug 21, 2026 | A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets… NCT07487740 · Healthy Participants NAL ER | TRVI Trevi Therapeutics | Phase 1 | Completed | 60 | May 11, 2026 | Registry ↗ |
| Aug 3, 2026 | NAL ER IPF Respiratory Function and Safety Study NCT07036029 · Idiopathic Pulmonary Fibrosis NAL ER, Placebo | TRVI Trevi Therapeutics | Phase 1 | Completed | 9 | Jun 30, 2026 | Registry ↗ |
| Jun 26, 2026 | Cough Reduction in IPF With Nalbuphine ER NCT05964335 · Idiopathic Pulmonary Fibrosis NAL ER, Placebo | TRVI Trevi Therapeutics | Phase 2 | Completed | 165 | Apr 24, 2025 | Registry ↗ |
| Mar 30, 2026 | Refractory Chronic Cough Improvement Via NAL ER (RIVER) NCT05962151 · Refractory Chronic Cough NAL ER, Placebo | TRVI Trevi Therapeutics | Phase 2 | Completed | 66 | Jan 6, 2025 | Registry ↗ |
| Mar 19, 2026 | Study of Nalbuphine ER in Participants With Hepatic Impairment NCT04020016 · Hepatic Impairment Nalbuphine ER | TRVI Trevi Therapeutics | Phase 1 | Completed | 28 | Feb 5, 2020 | Registry ↗ |
| Oct 10, 2025 | A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended… NCT07015398 · Healthy Participants NAL ER, Pirfenidone | TRVI Trevi Therapeutics | Phase 1 | Completed | 132 | Sep 12, 2025 | Registry ↗ |
| Jun 24, 2025 | PRISM Study-Pruritus Relief Through Itch Scratch Modulation NCT03497975 · Prurigo Nodularis Nalbuphine ER Tablets, Placebo Tablets | TRVI Trevi Therapeutics | Phase 2/3 | Completed | 353 | May 10, 2022 | Registry ↗ |
| May 29, 2025 | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of… NCT04030026 · Idiopathic Pulmonary Fibrosis NAL ER, Placebo | TRVI Trevi Therapeutics | Phase 2 | Completed | 42 | May 27, 2022 | Registry ↗ |
| May 22, 2025 | Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus NCT02373215 · Uremic Pruritus Nalbuphine HCL ER | TRVI Trevi Therapeutics | Phase 1 | Completed | 22 | Nov 2013 | Registry ↗ |
| May 21, 2025 | Oral Abuse Potential Study of Nalbuphine NCT04018664 · Nalbuphine, Opioid Abuse Nalbuphine HCl solution, Placebo solution | TRVI Trevi Therapeutics | Phase 1 | Completed | 56 | Dec 3, 2018 | Registry ↗ |
| May 21, 2025 | Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis NCT02174432 · Prurigo Nodularis, Nodularis Prurigo nalbuphine HCl ER | TRVI Trevi Therapeutics | Phase 2/3 | Completed | 36 | Sep 3, 2017 | Registry ↗ |
| May 21, 2025 | Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis NCT02174419 · Prurigo Nodularis, Nodularis Prurigo nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tabl… | TRVI Trevi Therapeutics | Phase 2/3 | Completed | 62 | Aug 2016 | Registry ↗ |
| May 21, 2025 | Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus NCT02143973 · Uremic Pruritus, Pruritus nalbuphine HCl ER | TRVI Trevi Therapeutics | Phase 2/3 | Completed | 167 | Jan 2016 | Registry ↗ |
| May 21, 2025 | Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus NCT02143648 · Uremic Pruritus, Pruritus nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tabl… | TRVI Trevi Therapeutics | Phase 2/3 | Completed | 373 | Jul 2015 | Registry ↗ |
17 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances